PT2976360T - Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro - Google Patents

Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro

Info

Publication number: PT2976360T
Authority: PT; Portugal
Prior art keywords: claudine; cancer; treatment; antibodies against; therapy involving
Prior art date: 2013-03-18

Application number

PT147145866T

Other languages

English (en)

Original Assignee

Astellas Pharma Inc

Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-18

Filing date

2014-03-17

Publication date

2020-01-22

2014-03-17 Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc

2020-01-22 Publication of PT2976360T publication Critical patent/PT2976360T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- G01N33/5753—
- G01N33/57585—
- G01N33/5759—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Food Science & Technology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT147145866T 2013-03-18 2014-03-17 Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro PT2976360T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2013/000817 WO2014146672A1 (en)	2013-03-18	2013-03-18	Therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number	Publication Date
PT2976360T true PT2976360T (pt)	2020-01-22

Family

ID=48182875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147145866T PT2976360T (pt)	2013-03-18	2014-03-17	Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro

Country Status (18)

Country	Link
US (3)	US10137195B2 (pt)
JP (5)	JP6416197B2 (pt)
KR (3)	KR102490997B1 (pt)
CN (1)	CN105189554B (pt)
AU (5)	AU2014234684B2 (pt)
BR (1)	BR112015023910B1 (pt)
CA (1)	CA2899770C (pt)
DK (1)	DK2976360T3 (pt)
ES (1)	ES2765949T3 (pt)
HU (1)	HUE048541T2 (pt)
IL (3)	IL299004B2 (pt)
MX (2)	MX372883B (pt)
MY (1)	MY191040A (pt)
PT (1)	PT2976360T (pt)
RU (1)	RU2678700C2 (pt)
SG (2)	SG11201507764QA (pt)
UA (1)	UA119036C2 (pt)
WO (2)	WO2014146672A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR102381936B1 (ko)	2012-11-13	2022-04-01	비온테크 에스이	클라우딘 발현 암 질환의 치료제
WO2014146672A1 (en) *	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) *	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Drug conjugates comprising antibodies against claudin 18.2
WO2016165765A1 (en) *	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016180468A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
CA3030257A1 (en) *	2016-07-08	2018-01-11	Carsgen Therapeutics Co., Ltd.	Antibody for anti-claudin 18a2 and use thereof
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
KR102784161B1 (ko)	2018-03-08	2025-03-19	페인스 테라퓨틱스 인코포레이티드	항-클라우딘 18.2 항체 및 이의 용도
KR20220103820A (ko) *	2018-05-18	2022-07-22	라노바 메디신즈 리미티드 컴파니	항-클라우딘 18.2 항체 및 이의 사용
EP3808376A4 (en)	2018-06-17	2021-09-01	L&L Biopharma Co., Ltd.	TARGET ANTIBODIES CLDN18.2, BISPECIFIC ANTIBODIES, ADC AND CAR, AND THEIR APPLICATIONS
CN112513093B (zh) *	2018-07-18	2024-08-09	奥美药业有限公司	一种新型抗体及其制备方法和应用
WO2020023702A1 (en)	2018-07-25	2020-01-30	AskGene Pharma, Inc.	Novel il-21 prodrugs and methods of use thereof
AR114541A1 (es) *	2018-08-03	2020-09-16	Amgen Res Munich Gmbh	Constructos de anticuerpos para cldn18.2 y cd3
US20220119517A1 (en) *	2018-08-27	2022-04-21	Nanjing Sanhome Pharmaceutical Co., Ltd.	Anti-claudin18.2 antibody and use thereof
KR20210072027A (ko) *	2018-09-30	2021-06-16	카파 테라퓨틱스 리미티드	Cldn18의 항체 및 화학요법 약물의 병용 요법
CA3122135A1 (en) *	2018-12-07	2020-06-11	Zlip Holding Limited	Anti-claudin antibodies and uses thereof
US12297265B2 (en)	2018-12-28	2025-05-13	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Antibody and use thereof
CN109762067B (zh) *	2019-01-17	2020-02-28	北京天广实生物技术股份有限公司	结合人Claudin 18.2的抗体及其用途
CN113825771B (zh) *	2019-05-16	2024-02-09	齐鲁制药有限公司	针对密蛋白18a2的抗体及其应用
CN117659190A (zh) *	2019-05-16	2024-03-08	启愈生物技术(上海)有限公司	抗cldn抗体及其药物组合物和检测方法
JP7600218B2 (ja) *	2019-05-24	2024-12-16	サンヨウバイオファーマシューティカルズカンパニーリミテッド	新規なｃｌｄｎ１８．２結合分子
BR112021023897A2 (pt) *	2019-05-30	2022-01-25	Shandong Boan Biotechnology Co Ltd	Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
KR102777693B1 (ko)	2019-07-17	2025-03-07	더 리전트 오브 더 유니버시티 오브 캘리포니아	Claudin18 항체 및 암 치료 방법
BR112021008870A2 (pt) *	2019-08-12	2021-11-30	Abl Bio Inc	Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
US20220306765A1 (en) *	2019-08-20	2022-09-29	Suzhou Transcenta Therapeutics Co., Ltd.	Novel anti-cldn18.2 antibodies
WO2021047599A1 (en) *	2019-09-13	2021-03-18	Beijing Xuanyi Pharmasciences Co., Ltd.	Humanized anti-claudin 18.2 (cldn18.2) antibodies
CN112707965A (zh)	2019-09-30	2021-04-27	和铂医药(苏州)有限公司	靶向cldn18.2的抗体及其制备方法和应用
WO2021111003A1 (en) *	2019-12-06	2021-06-10	SOTIO a.s.	Humanized cldn18.2 antibodies
JP2023527937A (ja) *	2020-05-25	2023-06-30	スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド	抗ｃｌｄｎ１８．２抗体及びその診断用途
CN113735974B (zh) *	2020-05-29	2023-10-27	杭州邦顺制药有限公司	针对Claudin18.2的抗体及其用途
CN116284403A (zh) *	2020-06-23	2023-06-23	德琪(杭州)生物有限公司	用于治疗claudin相关疾病的抗体和方法
CN111777681B (zh) *	2020-07-06	2022-10-11	康诺亚生物医药科技（成都）有限公司	一种结合紧密连接蛋白-18.2的抗体及其用途
CN111808194B (zh) *	2020-07-13	2021-04-20	北京凯因科技股份有限公司	一种结合密蛋白的用于治疗癌症的人源化抗体
CA3194771A1 (en)	2020-09-16	2022-03-24	Amgen Inc.	Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022100590A1 (zh) *	2020-11-10	2022-05-19	齐鲁制药有限公司	针对密蛋白18a2的adcc增强型人源化抗体及其应用
CN114805571B (zh) *	2021-01-28	2023-08-25	广西鹭港生物医药科技有限公司	抗cldn18.2抗体及其应用
US20240342215A1 (en)	2021-07-14	2024-10-17	Regeneron Pharmaceuticals, Inc.	Engineered t cell receptors fused to binding domains from antibodies
WO2023016348A1 (en)	2021-08-09	2023-02-16	Harbour Biomed (Shanghai) Co., Ltd	Cldn18.2-targeting antibody, bispecific antibody and use thereof
AU2023251117A1 (en)	2022-04-08	2024-11-21	Regeneron Pharmaceuticals, Inc.	Multipartite receptor and signaling complexes
CN117229398A (zh) *	2022-06-15	2023-12-15	中山康方生物医药有限公司	抗cldn18.2抗体、其药物组合物及用途
EP4628507A1 (en)	2022-11-29	2025-10-08	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Cldn18.2/4-1bb binding protein and medical use thereof
CN119101162A (zh) *	2023-06-07	2024-12-10	江苏奥赛康生物医药有限公司	一种抗cldn18_2的抗体及体外诊断试剂盒
WO2025034702A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors
CN117567625B (zh) *	2023-11-21	2025-07-22	中国医学科学院医药生物技术研究所	一种抗Claudin18.2单克隆抗体及其应用
CN117701719B (zh) *	2024-02-04	2024-05-31	北京肿瘤医院(北京大学肿瘤医院)	肿瘤靶向cldn18.2治疗耐药标志物及其应用
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
CN119143798B (zh) *	2024-08-01	2025-09-30	河北医科大学	一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
WO2001054708A1 (en)	2000-01-31	2001-08-02	Human Genome Sciences, Inc.	22 human secreted proteins
WO2000012708A2 (en)	1998-09-01	2000-03-09	Genentech, Inc.	Further pro polypeptides and sequences thereof
WO2000078961A1 (en)	1999-06-23	2000-12-28	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1144629A3 (en)	1998-09-01	2001-11-28	Genentech, Inc.	Further pro polypeptides and sequences thereof
EP1112364A2 (en)	1998-09-16	2001-07-04	ZymoGenetics, Inc.	Stomach polypeptide zsig28
CA2345377A1 (en)	1998-10-06	2000-04-13	Curagen Corporation	Novel secreted proteins and polynucleotides encoding them
EP1165784A2 (en)	1999-03-31	2002-01-02	Curagen Corporation	Nucleic acids including open reading frames encoding polypeptides; "orfx"
EP1208202A2 (en)	1999-09-01	2002-05-29	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6380362B1 (en)	1999-12-23	2002-04-30	Genesis Research & Development Corporation Ltd.	Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP1254151A1 (en)	2000-01-31	2002-11-06	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
WO2001055326A2 (en)	2000-01-31	2001-08-02	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
AU2001241408A1 (en)	2000-01-31	2001-08-07	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
AU6802801A (en)	2000-03-01	2001-09-24	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en)	2000-03-31	2002-08-20	Hyseq, Inc.	Nucleic acids and polypeptides
WO2001090357A1 (en)	2000-05-24	2001-11-29	Genesis Research & Development Corporation Limited	Compositions isolated from skin cells and methods for their use
ATE363531T1 (de)	2000-08-15	2007-06-15	Immunex Corp	Claudin polypeptide
EP1328635A2 (en)	2000-08-28	2003-07-23	Diadexus, Inc.	Compositions and methods relating to lung specific genes
JP2004509617A (ja)	2000-09-08	2004-04-02	シェーリング　コーポレイション	哺乳動物遺伝子；関連試薬および方法
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
ES2524694T3 (es)	2002-10-17	2014-12-11	Genmab A/S	Anticuerpos monoclonales humanos contra CD20
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20050181375A1 (en)	2003-01-10	2005-08-18	Natasha Aziz	Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004042822A1 (de)	2004-08-31	2006-03-16	Technische Universität Dresden	Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
EP2182057A1 (en)	2005-08-31	2010-05-05	Cell Signaling Technology, Inc.	Antibody agains phosphorylated Tyrosine for the detection of protein phosphorylation in carcinoma signaling pathways
BRPI0616090A2 (pt)	2005-09-19	2011-06-07	Veridex, Llc	métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida
EP1790664A1 (en) *	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
CA2638040A1 (en) *	2006-02-09	2007-08-16	Micromet Ag	Treatment of metastatic breast cancer
WO2008013948A2 (en)	2006-07-27	2008-01-31	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
CA2677118A1 (en)	2007-02-01	2008-08-07	Veridex, Llc	Methods and materials for identifying the origin of a carcinoma of unknown primary origin
EP1970384A1 (en) *	2007-03-14	2008-09-17	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2145902A3 (en)	2007-04-19	2010-09-29	Peter Hornbeck	Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008152822A1 (ja)	2007-06-15	2008-12-18	Medinet Co., Ltd.	医薬
EP2036987A1 (en)	2007-09-17	2009-03-18	Siemens Healthcare Diagnostics GmbH	Molecular markers for tumor cell content in tissue samples
WO2010141093A2 (en)	2009-06-04	2010-12-09	The University Of Maryland, Baltimore	Co-signaling methods for treating cancers
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
WO2013174403A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en)	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en)	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Therapy involving antibodies against claudin 18.2 for treatment of cancer

2013
- 2013-03-18 WO PCT/EP2013/000817 patent/WO2014146672A1/en not_active Ceased
2014
- 2014-03-17 RU RU2015144666A patent/RU2678700C2/ru active
- 2014-03-17 DK DK14714586.6T patent/DK2976360T3/da active
- 2014-03-17 KR KR1020157025855A patent/KR102490997B1/ko active Active
- 2014-03-17 MX MX2015013355A patent/MX372883B/es active IP Right Grant
- 2014-03-17 KR KR1020247019155A patent/KR20240096827A/ko active Pending
- 2014-03-17 CA CA2899770A patent/CA2899770C/en active Active
- 2014-03-17 KR KR1020237001955A patent/KR20230015514A/ko not_active Ceased
- 2014-03-17 BR BR112015023910-2A patent/BR112015023910B1/pt active IP Right Grant
- 2014-03-17 HU HUE14714586A patent/HUE048541T2/hu unknown
- 2014-03-17 SG SG11201507764QA patent/SG11201507764QA/en unknown
- 2014-03-17 JP JP2016503569A patent/JP6416197B2/ja active Active
- 2014-03-17 CN CN201480013032.3A patent/CN105189554B/zh active Active
- 2014-03-17 AU AU2014234684A patent/AU2014234684B2/en active Active
- 2014-03-17 UA UAA201510107A patent/UA119036C2/uk unknown
- 2014-03-17 SG SG10201707684WA patent/SG10201707684WA/en unknown
- 2014-03-17 MY MYPI2015002398A patent/MY191040A/en unknown
- 2014-03-17 IL IL299004A patent/IL299004B2/en unknown
- 2014-03-17 WO PCT/EP2014/000719 patent/WO2014146778A1/en not_active Ceased
- 2014-03-17 ES ES14714586T patent/ES2765949T3/es active Active
- 2014-03-17 US US14/777,231 patent/US10137195B2/en active Active
- 2014-03-17 PT PT147145866T patent/PT2976360T/pt unknown
- 2014-03-17 IL IL305017A patent/IL305017A/en unknown
2015
- 2015-07-21 IL IL240060A patent/IL240060B2/en unknown
- 2015-09-18 MX MX2020003719A patent/MX2020003719A/es unknown
2018
- 2018-06-13 JP JP2018112553A patent/JP7018361B2/ja active Active
- 2018-10-11 US US16/158,187 patent/US11395852B2/en active Active
2019
- 2019-03-05 AU AU2019201513A patent/AU2019201513B2/en active Active
2020
- 2020-06-03 JP JP2020096842A patent/JP7166310B2/ja active Active
- 2020-07-27 AU AU2020210165A patent/AU2020210165B2/en active Active
2022
- 2022-03-04 US US17/653,638 patent/US20220184209A1/en not_active Abandoned
- 2022-07-07 JP JP2022109564A patent/JP7633968B2/ja active Active
- 2022-10-07 AU AU2022246477A patent/AU2022246477B2/en active Active
2024
- 2024-02-08 JP JP2024017596A patent/JP7798932B2/ja active Active
2025
- 2025-07-10 AU AU2025205333A patent/AU2025205333A1/en active Pending

Also Published As

Publication number	Publication date
SG10201707684WA (en)	2017-11-29
WO2014146778A1 (en)	2014-09-25
KR20150130318A (ko)	2015-11-23
CA2899770C (en)	2025-05-27
IL299004B2 (en)	2024-02-01
CN105189554A (zh)	2015-12-23
IL240060B2 (en)	2023-05-01
JP2018184403A (ja)	2018-11-22
MY191040A (en)	2022-05-30
US20190076525A1 (en)	2019-03-14
HK1219486A1 (en)	2017-04-07
JP2020143153A (ja)	2020-09-10
MX2015013355A (es)	2016-06-24
NZ710648A (en)	2021-03-26
JP7633968B2 (ja)	2025-02-20
AU2020210165A1 (en)	2020-08-13
JP7798932B2 (ja)	2026-01-14
IL299004A (en)	2023-02-01
MX372883B (es)	2020-07-08
RU2019101923A (ru)	2019-02-22
KR20230015514A (ko)	2023-01-31
US11395852B2 (en)	2022-07-26
ES2765949T3 (es)	2020-06-11
AU2014234684A1 (en)	2015-08-20
IL305017A (en)	2023-10-01
AU2022246477A1 (en)	2022-11-03
MX2020003719A (es)	2020-07-22
AU2014234684B2 (en)	2018-12-06
RU2015144666A3 (pt)	2018-03-26
UA119036C2 (uk)	2019-04-25
US20160008465A1 (en)	2016-01-14
IL240060B1 (en)	2023-01-01
AU2022246477B2 (en)	2025-04-17
JP2024056803A (ja)	2024-04-23
SG11201507764QA (en)	2015-10-29
AU2019201513B2 (en)	2020-08-13
IL299004B1 (en)	2023-10-01
RU2015144666A (ru)	2017-04-21
AU2020210165B2 (en)	2022-07-14
ES2765949T8 (es)	2020-06-23
KR20240096827A (ko)	2024-06-26
AU2025205333A1 (en)	2025-07-31
RU2678700C2 (ru)	2019-01-31
HUE048541T2 (hu)	2020-07-28
CN105189554B (zh)	2021-10-08
CA2899770A1 (en)	2014-09-25
BR112015023910A2 (pt)	2017-03-21
JP7018361B2 (ja)	2022-02-10
BR112015023910B1 (pt)	2019-09-10
AU2019201513A1 (en)	2019-03-28
US10137195B2 (en)	2018-11-27
IL240060A0 (en)	2015-09-24
US20220184209A1 (en)	2022-06-16
WO2014146672A1 (en)	2014-09-25
KR102490997B1 (ko)	2023-01-25
JP6416197B2 (ja)	2018-10-31
JP2016517447A (ja)	2016-06-16
DK2976360T3 (da)	2020-01-27
JP7166310B2 (ja)	2022-11-07
JP2022133424A (ja)	2022-09-13

Publication	Publication Date	Title
PT2976360T (pt)	2020-01-22	Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
IL302093B1 (en)	2026-01-01	Combination therapy involving anti-claudin 18.2 antibodies for cancer treatment
LT3283527T (lt)	2021-03-25	Kompleksinė terapija vėžio gydymui
HRP20220897T8 (hr)	2022-11-11	Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
LT3033086T (lt)	2021-12-27	Kombinuota terapija vėžiui gydyti
HUE046674T2 (hu)	2020-03-30	B7-H1 elleni antitestek tumorok kezelésére
HUE059694T2 (hu)	2022-12-28	Készítmény rák kezelésére
HUE036000T2 (hu)	2018-06-28	Claudin 18.2 ellen irányuló antitesteket magában foglaló kombinációs terápia rák kezelésére
HUE053191T2 (hu)	2021-06-28	2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
KR20180084772A (ko)	2018-07-25	암 치료를 위한 조합 치료법
ZA201706402B (en)	2019-01-30	C.novyi for the treatment of solid tumors in humans
PT3511004T (pt)	2024-09-03	Preparações combinadas para o tratamento de cancro
HUE053648T2 (hu)	2021-07-28	Gyógyászati kombinációk rák kezelésére
IL245551A0 (en)	2016-06-30	Anti-matriptase antibodies for cancer treatment
HUE047920T2 (hu)	2020-05-28	GD2-pozitív rák kezelésére szolgáló készítmények
HUE049301T2 (hu)	2020-09-28	Kurkofenol-vegyület rák kezelésére
SMT202200458T1 (it)	2023-01-13	Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PT2984108T (pt)	2017-09-19	Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
KR20180084983A (ko)	2018-07-25	암의 치료를 위한 피리미도-피리미다지논의 용도
PT3065751T (pt)	2020-03-06	Processo para o tratamento do cancro e das comorbidades do cancro
PL2976360T3 (pl)	2020-05-18	Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
EP2991650A4 (en)	2017-01-25	Methods for the treatment of cancer
EP3016948B8 (en)	2017-07-19	2-acylaminothiazoles for the treatment of cancer